| Ms Linda Irene Grayson, LCSW | |
|
820 Jordan St Ste 570, Shreveport, LA 71101-4512 | |
| (318) 221-4455 | |
| (318) 221-5599 |
| Full Name | Ms Linda Irene Grayson |
|---|---|
| Gender | Female |
| Speciality | Clinical Social Worker |
| Experience | 19 Years |
| Location | 820 Jordan St Ste 570, Shreveport, Louisiana |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669626842 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 8982 (Louisiana) | Primary |
| Entity Name | Interactional Services, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891821641 PECOS PAC ID: 5799677647 Enrollment ID: O20040326000264 |
News Archive
A research study published in the journal Neoplasia and led by principal investigator Nallasivam Palanisamy, Ph.D., associate scientist in the Vattikuti Urology Institute at Henry Ford Health System, has identified a novel prostate cancer gene fusion involving the KLK4 protein coding gene and KLKP1 pseudogene.
Today's health policy headlines include reports about health law funding and policy particulars, as well as Dems' push to protect Medicaid.
An anti-inflammatory drug Ruxolitinib has shown promising results in the treatment of severe coronavirus disease COVID-19. The study titled, "Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial," was published as a pre-proof for the Journal of Allergy and Clinical Immunology.
Targeted therapy with BRAF-MEK inhibitors is an effective treatment for patients with advanced melanoma that cannot be surgically removed or has spread to other areas of the body.
› Verified 9 days ago
| Entity Name | Linda Grayson Lcsw Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336855279 PECOS PAC ID: 7719358282 Enrollment ID: O20230427002232 |
News Archive
A research study published in the journal Neoplasia and led by principal investigator Nallasivam Palanisamy, Ph.D., associate scientist in the Vattikuti Urology Institute at Henry Ford Health System, has identified a novel prostate cancer gene fusion involving the KLK4 protein coding gene and KLKP1 pseudogene.
Today's health policy headlines include reports about health law funding and policy particulars, as well as Dems' push to protect Medicaid.
An anti-inflammatory drug Ruxolitinib has shown promising results in the treatment of severe coronavirus disease COVID-19. The study titled, "Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial," was published as a pre-proof for the Journal of Allergy and Clinical Immunology.
Targeted therapy with BRAF-MEK inhibitors is an effective treatment for patients with advanced melanoma that cannot be surgically removed or has spread to other areas of the body.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Linda Irene Grayson, LCSW 820 Jordan St Ste 570, Shreveport, LA 71101-4512 Ph: (318) 221-4455 | Ms Linda Irene Grayson, LCSW 820 Jordan St Ste 570, Shreveport, LA 71101-4512 Ph: (318) 221-4455 |
News Archive
A research study published in the journal Neoplasia and led by principal investigator Nallasivam Palanisamy, Ph.D., associate scientist in the Vattikuti Urology Institute at Henry Ford Health System, has identified a novel prostate cancer gene fusion involving the KLK4 protein coding gene and KLKP1 pseudogene.
Today's health policy headlines include reports about health law funding and policy particulars, as well as Dems' push to protect Medicaid.
An anti-inflammatory drug Ruxolitinib has shown promising results in the treatment of severe coronavirus disease COVID-19. The study titled, "Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial," was published as a pre-proof for the Journal of Allergy and Clinical Immunology.
Targeted therapy with BRAF-MEK inhibitors is an effective treatment for patients with advanced melanoma that cannot be surgically removed or has spread to other areas of the body.
› Verified 9 days ago
Karl Reichter, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 510 E Stoner Ave, Shreveport, LA 71101 Phone: 319-990-4401 | |
Mrs. Chelsey Vincent, LMSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 856 Texas Ave, Shreveport, LA 71101 Phone: 318-429-6938 | |
Kemeco Taylor-small, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 510 E Stoner Ave, Shreveport, LA 71101 Phone: 318-221-8411 Fax: 318-990-5599 | |
Mr. Dock Voorhies, SOCIAL WORKER Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 510 E Stoner Ave, Shreveport, LA 71101 Phone: 318-424-6040 Fax: 318-424-6121 | |
Danielle Bailey, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 4111 Pines Rd Unit 65, Shreveport, LA 71119 Phone: 318-613-0147 | |
Charles Lee, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 6654 Gilbert Pl, Shreveport, LA 71106 Phone: 318-865-4360 | |
Mr. Andrew Wilson, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 6007 Financial Plz Ste 213, Shreveport, LA 71129 Phone: 318-458-5158 Fax: 318-220-8108 |